What is the diagnostic approach for suspected carcinoid syndrome?

Diagnosis of Carcinoid Syndrome

When carcinoid syndrome is suspected, obtain a 24-hour urine collection for 5-hydroxyindoleacetic acid (5-HIAA) and measure serum chromogranin A as baseline biochemical tests. 1, 2

Clinical Recognition

Carcinoid syndrome typically presents with:

• Flushing (particularly upper thorax and face)
• Secretory diarrhea
• Bronchoconstriction/wheezing
• Cardiac involvement (tricuspid regurgitation, pulmonary stenosis in 50-66% of cases) 2, 3

The syndrome occurs in only 8-28% of patients with neuroendocrine tumors and usually requires liver metastases or retroperitoneal disease, since metabolic products are rapidly destroyed by hepatic enzymes in the portal circulation 2, 1.

Biochemical Diagnostic Approach

Primary Tests

• 24-hour urinary 5-HIAA: The diagnostic standard with ~90% specificity 3

  • Critical caveat: Avoid false positives by restricting foods/medications 48 hours before collection:
    • Foods: banana, avocado, eggplant, pineapple, plums, walnuts
    • Medications: paracetamol, fluorouracil, methysergide, naproxen, caffeine 1
  • False negatives occur with: levodopa, aspirin, ACTH, methyldopa, phenothiazines 1

• Serum chromogranin A (CgA): Highest reliability among NET biomarkers (75% sensitivity in carcinoid tumors) 3

  • Particularly useful in gastric carcinoids with metastases 1
  • Elevated in most NETs regardless of secretory status 1

Additional Markers (When Appropriate)

Consider based on clinical presentation: calcium, thyroid function tests, PTH, calcitonin, prolactin, alpha-fetoprotein, CEA, beta-HCG 1

Imaging Strategy

After biochemical confirmation, proceed with anatomic and functional imaging:

Anatomic Imaging

• Multiphase CT or MRI of chest/abdomen/pelvis (NETs are highly vascular and can appear isodense on conventional CT) 2
• Site-specific endoscopy as indicated:
  • Colonoscopy/small bowel imaging for jejunal/ileal/colonic NETs
  • EGD/EUS for gastric/duodenal NETs
  • Bronchoscopy for bronchopulmonary NETs 2

Functional Imaging

• Somatostatin receptor scintigraphy (Octreoscan): 80% of bronchopulmonary NETs express somatostatin receptors 4
  • Sensitivity 61-96% for detecting metastases 1
  • 68Ga-DOTATATE PET/CT offers superior sensitivity/specificity in contemporary practice 5

Histological Confirmation

Histology remains the gold standard and should be obtained whenever possible 1. This allows:

• Definitive diagnosis
• Assessment of proliferation indices (Ki-67)
• Grading (typical vs atypical carcinoid)
• Treatment planning

Special Considerations

Bronchopulmonary Carcinoids

• Measure plasma chromogranin A as baseline 4
• When hormone-related symptoms present: plasma ACTH, GHRH, IGF-I, urine cortisol, 5-HIAA 4
• Cushing syndrome workup if hypercortisolemia suspected 2, 3

Cardiac Screening

Annual echocardiography is mandatory when carcinoid syndrome is present or 5-HIAA levels are elevated to screen for carcinoid heart disease 6, 7

Diagnostic Pitfalls

1. False-negative biochemistry: Some patients present with isolated flushing and negative 5-HIAA/chromogranin A; imaging becomes critical 5
2. Delayed diagnosis: Average diagnostic delay is substantial because flushing and diarrhea are often attributed to other causes 8
3. Carcinoid crisis risk: Recognition before invasive procedures is essential—crisis can be precipitated by anesthesia, surgery, biopsy, or adrenergic drugs 3

Algorithmic Summary

1. Clinical suspicion → Obtain 24-hour urine 5-HIAA + serum chromogranin A (with dietary restrictions)
2. Positive biochemistry → Multiphase CT/MRI + somatostatin receptor imaging
3. Locate primary → Site-specific endoscopy based on imaging findings
4. Obtain histology → Biopsy for definitive diagnosis and grading
5. Cardiac evaluation → Echocardiography if syndrome confirmed
6. Perioperative planning → IV octreotide prophylaxis if procedures needed 3